AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1. The inhalers treat asthma and chronic obstructive pulmonary disease, which combined affect roughly 41 million Americans…

Read more...